Skip to contents

Ankylosing Spondylitis.

Source: R/AS.R
AS.Rd

Data set containing historical information for placebo for a phase II trial of ankylosing spondylitis patients. The primary efficacy endpoint was the percentage of patients with a 20% response according to the Assessment of SpondyloArthritis international Society criteria for improvement (ASAS20) at week 6.

Usage

AS

Format

A data frame with 8 rows and 3 variables:

study

study

n

study size

r

number of events

References

Baeten D, others (2013). “Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.” The Lancet, 382(9906), 1705–1713. doi:10.1016/S0140-6736(13)61134-4 .

Examples

.user_mc_options <- options()

set.seed(34563)
map_AS <- gMAP(cbind(r, n - r) ~ 1 | study,
  family = binomial,
  data = AS,
  tau.dist = "HalfNormal", tau.prior = 1,
  beta.prior = 2
)
#> Assuming default prior location   for beta: 0
## Recover user set sampling defaults
options(.user_mc_options)